Abstract: An object of the present invention is to provide a fermented milk and polysaccharide capable of inhibiting cancerous cachexia. A fermented milk with cancerous cachexia inhibitory effect according to one aspect of the present invention contains Lactobacillus delbrueckii subsp. bulgaricus as an active ingredient. Also, polysaccharide with cancerous cachexia inhibitory effect according to another aspect of the present invention are produced from the Lactobacillus delbrueckii subsp. bulgaricus. It is preferable that the Lactobacillus delbrueckii subsp. bulgaricus is Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (accession number: FERM BP-10741).

Abstract: The invention relates to prevention of insulin resistance or low-grade chronic inflammation later in life upon ingestion of synbiotics early in life.

Abstract: The invention relates to improved liver health and lipid metabolism later in life upon ingestion of synbiotics early in life.

Abstract: The present application provides methods of functionalizing an organ or tissue of a mammal by administering a nutrient (e.g., peracetylated N-azido galactosamine Ac4GalNAz) to the mammal or by culturing an organ or tissue in a bioreactor containing such nutrient. The present application also provides methods of selectively functionalizing extracellular matrix (ECM) of an organ or tissue of a mammal by administering a nutrient (e.g., peracetylated N-azido galactosamine Ac4GalNAz) to the mammal. In some aspects, the present application provides a decellularized scaffold of a mammalian organ or tissue comprising an extracellular matrix, wherein the extracellular matrix of the decellularized scaffold is functionalized with a chemical group that is reactive in a bioorthogonal chemical reaction, such as an azide chemical group. The present application also provides biological prosthetic mesh and mammalian organs and tissues for transplantation prepared according to the methods of the application.

Abstract: The present invention provides a method of treating a disease or condition characterized by inflammation in a subject in need thereof, comprising administering to the subject an effective amount of a Pediococcus acidilactici probiotic. Compositions of Pediococcus acidilactici probiotic are also provided.

Abstract: Systems and methods for conducting assays on tissue fragment samples including providing a suspension maintaining pump, and a plurality of fluid reservoirs, wherein the fluid reservoirs are configured to hold a volume of fluid. The fluid reservoirs are fluidically coupled to a microfluidic assay chip, wherein the microfluidic assay chip includes a plurality of parallel assay channels, a first inlet port for introduction of a tissue fragment sample into the microfluidic assay ship, and a second inlet port coupled to the fluid reservoir. Each channel of the microfluidic assay chip also includes a retention barrier configured to trap the tissue fragment sample such that the fluid perfuses through the tissue sample, as well as an outlet port fluidically coupled to a waste receptacle.

Abstract: The present invention provides a Bifidobacterium lactis GKK2, a composition comprising thereof and its use for improving asthma, especially for lowering airway resistance, reducing levels of non-specific and specific IgE in serum, alleviating bronchoconstriction and increasing levels of GSH reductase in liver tissue interstitial fluid to improve allergic asthma.

Abstract: Methods for treating a bioprosthetic tissue are described herein. The methods comprise contacting the bioprosthetic tissue with at least one nucleophile and/or at least one electrophile in the presence of a catalytic system comprising at least one or a combination of a fluoride-based salt, a cesium-based salt, a potassium-based salt, a rubidium-based salt, or a carbonate-based salt. The methods may be used to alter functional groups on biological tissue which represent actual and potential calcium binding sites and also processes for cross-linking bioprosthetic tissue. Both processes may be used in conjunction with known fixative techniques, such as glutaraldehyde fixation, or may be used to replace known fixative techniques.

Abstract: Disclosed herein are compositions including cells of defined sets of microbial species (for example, 3, 16, 18, 19, 21, or 22 microbial species). Also disclosed are methods of using the microbial compositions that include contacting soil, plants, plant parts, or seeds with the composition. The microbial compositions are also used in methods of degrading biological materials, such as chitin-containing biological materials.

Abstract: Disclosed herein are methods and compositions related to probiotic formulas. These formulas comprise the bacterial strain Lactobacillus crispatus WZ-12 or a derivative thereof. Other strains which can be included in the composition include, but are not limited to, Lactobacillus salivarius 1-14, or Lactobacillus reuteri 2-2, and derivatives thereof. These compositions can be used in a variety of methods to treat and/or ameliorate diseases, such as colonization of antibiotic-resistant bacteria in the host organism. Also disclosed herein are methods of treating those subjects in need thereof by administering the compositions disclosed herein.

Abstract: In some aspects, methods and probiotic compositions are provided for the treatment of bone diseases such as, e.g., ostetoporosis. In some embodiments, one or more bacteria from the warm microbiota such as, e.g., Clostridialeace-assimilate, Lactobacillus, Bifidobacteriaceae, Akkermansia, and/or Parabacteroides may be administered to a subject, such as a human subject, to treat the bone disease. In some embodiments, heat may be applied to the subject to promote the development of warm microbiota to treat the bone disease.

Abstract: A method and particle analyzer for measuring a low concentration particles sample disclosed.

Abstract: The invention relates to the use of matrix cells for obtaining a micro hair follicle and to the use thereof for evaluating the effect of cosmetic, pharmaceutical or dermatological products and also for the prophylactic or therapeutic treatment of a state of reduced pilosity.

Abstract: A custom-made matrix suitable for receiving a tissue sample is described, as well as the use thereof to obtain a multiplex histological preparation. The disclosure also relates to a multiplex biopsy array comprising tissue and/or cell samples arranged in a matrix material and to a method for the preparation of a multiplex biopsy array. Methods for preparing blocks of matrix material to be used in multiplex biopsy arrays are also described, as well as methods for loading biopsy samples in the blocks, and methods for treating and processing the blocks to form biopsy arrays. The biopsy arrays made using the block of matrix material can be used to prepare sections and slides for histological procedures, including quantitative analyses and parallel processing.

Abstract: A system for the detection of pathogenic organisms in growth substrate or water is described which comprises means for the delivery of an attractant into the growth substrate or water, means for directing the microorganism to a detector for the detection of the microorganism of interest, and a detector which provides a signal when the microorganism of interest is detected, the use of the system in agriculture and horticulture is also described.

Abstract: Methods and systems for preparing a medium-embedded-sample-block. The method comprises obtaining a frame having a plurality of sample wells arranged as a two-dimensional array, the frame having an open face for accessing the sample in the sample wells; placing embedding medium in the sample wells such that the embedding medium immerses the samples in the plurality of sample wells; allowing the embedding medium to form a block of embedding medium including the samples embedded therein; and separating the frame from the block of embedding medium to obtain the medium-embedded-sample-block.

Abstract: The invention relates to a method for embedding a load based on gel high hydrostatic pressure liquefaction. Using the phenomenon that the physical gel is liquefied under high pressure, the vacuum-packaged high-methoxyl pectin gel is treated under a pressure of 400-600 MPa for 5-30 min, mixed with the load, and then subjected to a pressure of 400-600 MPa for homogenization treatment for 5 to 30 min. After pressure relief, the liquefied gel is poured into a mold for reshaping, followed by removal of free water and coating treatment. This method combines the advantages of high hydrostatic pressure technology in modification and sterilization. It has mild embedding conditions and wide sources of raw materials to prepare the carrier, which has excellent biocompatibility and biodegradability. It can be widely used for embedding microorganisms, enzymes, proteins and small molecular substances. The loaded gel prepared by the method has high microbial safety, can effectively maintain the activity of the load.

Abstract: The present invention relates to microbial cells, including but not limited to aerobic bacteria cells and anaerobic bacteria cells, as well as yeast cells, and methods for producing the cells, feed additives and compositions comprising the cells, and uses involving administration of the cells to animals.

Abstract: The present invention relates to a method for preventing and/or treating fatty liver and its related conditions in a subject, comprising administering an effective amount of plasminogen to the subject; in another aspect, the present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating fatty liver and its related conditions in the subject.

Abstract: Disclosed are compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are compositions comprising a previously cryopreserved umbilical tissue, wherein after cryopreservation and subsequent thawing the umbilical tissue comprises: a) viable cells native to the umbilical tissue; b) tissue integrity of native umbilical tissue; c) one or more growth factors that are native to the umbilical tissue; and d) depleted amounts of one or more types of functional immunogenic cells. Disclosed are methods of producing compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are methods of treating damaged tissue comprising administering to the site of the damaged tissue compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels.